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three different radiation techniques for patients
with Graves’ ophthalmopathy treated with
retro-orbital irradiation
Victor HF Lee1*, Sherry CY Ng1, Cheuk Wai Choi2, Mai Yee Luk1, To Wai Leung1, Gordon KH Au1
and Dora LW Kwong1Abstract
Background: We would like to investigate the if IMRT produced better target coverage and dose sparing to
adjacent normal structures as compared with 3-dimensional conformal radiotherapy (3DCRT) and lateral opposing
fields (LOF) for patients with Graves’ ophthalmopathy treated with retro-orbital irradiation.
Methods: Ten consecutive patients diagnosed with Graves’ ophthalmopathy were prospectively recruited into this
study. An individual IMRT, 3DCRT and LOF plan was created for each patient. Conformity index (CI), homogeneity
index (HI) and other dosimetric parameters of the targets and organs-at-risk (OAR) generated by IMRT were
compared with the other two techniques.
Results: Mann–Whitney U test demonstrated that CI generated by IMRT was superior to that produced by 3DCRT
and LOF (p=0.005 for both respectively). Similarly HI with IMRT was proven better than 3DCRT (p=0.007) and LOF
(p=0.005). IMRT gave rise to better dose sparing to some OARs including globes, lenses and optic nerves as
compared with 3DCRT but not with LOF.
Conclusions: IMRT, as compared with 3DCRT and LOF, was found to have a better target coverage, conformity and
homogeneity and dose sparing to some surrounding structures, despite a slight increase but clinically negligible
dose to other structures. Dosimetrically it might be a preferred treatment technique and a longer follow up is
warranted to establish its role in routine clinical use.
Keywords: Intensity-modulated radiation therapy, Graves’ ophthalmopathy, Retro-orbital irradiationIntroduction
Graves’ ophthalmopathy is an orbital inflammatory path-
ology associated with an underlying autoimmune thyroid
disease particularly Graves’ disease [1,2]. Radiotherapy
has long been used for this pathology, besides decom-
pressive and corrective surgery as well as systemic ster-
oids [1,3-5]. Traditionally a pair of lateral opposing fields
(LOF) directed to the orbital structures has been
adopted for decades in virtue of its easy set-up and* Correspondence: vhflee@hku.hk
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reproduction in any medium, provided the orprompt delivery. The beams are either blocked anteriorly
or tilted 5 degrees posteriorly to minimize dose to the
lenses. However, this will inevitably lead to inadequate
dose to parts of the orbital structures especially the
insertions of the extra-ocular muscles and the anterior
portions of the retro-orbital fat. More advanced tech-
nique including 3-dimensional conformal radiotherapy
(3DCRT), intensity modulated radiation therapy (IMRT)
and robotic stereotactic radiotherapy are increasingly
gaining popularity, due to their superior target coverage,
dose escalation to the targets and better radiation spar-
ing of normal structures [6-12]. In this study, we would
like to investigate if IMRT provides a better target cover-
age as well as superior dose sparing to the normal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Field arrangement by IMRT (uppermost), LOF (middle)
and 3DCRT (lowermost). Arrows indicate the directions of beams.
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patients treated with orbital irradiation for their Graves’
ophthalmopathy.
Methods
Ten consecutive patients with Graves’ ophthalmopathy
diagnosed by ophthalmologists between July 2009 and
June 2011 were treated with retro-orbital irradiation.
After immobilized by custom-made thermoplastic cast,
they underwent computed tomography (CT) scan with
slice thickness 2.5mm for image acquisition and target
contouring. The gross tumour volume (GTV) which was
also equivalent to clinical target volume (CTV) included
the retro-orbital fatty spaces together with the main
bulk, origins and insertions of the extra-ocular muscles
of both eyes. The globes, lenses, optic nerves, optic
chiasm and lacrimal glands were outlined as organs-
at-risk (OAR). A 2mm concentric margin around the
GTV was created by boolean operators of the Eclipse
Treatment Planning System version 8.9 (Varian Medical
Systems, Palo Alto, CA) to generate the planning target
volumes (PTV). All patients were given 10Gy in 10 frac-
tions over 2 weeks delivered by reversely planned 7-field
IMRT (directed at 0°, 40°, 80°, 110°, 250°, 280° and 320°),
using anisotropic analytical algorithm with a 2.5mm cal-
culation grid as planned by our treatment planning sys-
tem with objective functions to minimize the square of
dose difference between the constraints of the actual
dose. All IMRT plans were verified with MapCHECK
(SunNuclear) to ensure 90% pass for detector points
with γ index of 3% and 3mm before they were delivered
by a 4MV linear accelerator [13,14]. Anteroposterior and
lateral x-ray simulation was performed and compared
with electronic portal imaging at anteroposterior and lat-
eral directions performed to verify treatment position
before the first 3 fractions, 5th fraction and last fraction
of IMRT. All patients had anteroposterior and lateral
deviations of ≤1.5mm during the whole course of IMRT,
justifying the usual practice of giving 2mm margin
around GTV to generate PTV in our institution. A
separate LOF plan with the isocentres fixed at both
lateral bony canthi (blocking the anterior halves of the
beams) directed laterally to each side of the orbit and
a typical field size of 4.5cm (anteroposterior dimen-
sion) by 5.0cm (craniocaudal dimension) was gener-
ated. Another 3DCRT plan delivered by 6 beams (one
beam directed at gantry angle 270° with a 45-degree
wedge, 1 pair of beams at 344° with a 20-degree and
a 30-degree dynamic wedges, one pair of beams at 18°
with a 20-degree and a 30-degree dynamic wedges and
a beam directed at 90°) based on the same CT images
were also generated. Both LOF and 3DCRT were pro-
duced for each patient for statistical comparison of
dosimetric parameters (Figure 1). For 3DCRT andIMRT, though the total radiation dose would not exceed
the tolerance dose of the lenses, optic nerves and optic
chiasm, weightings were given during optimization pro-
cedures in an attempt to eliminate overdose (>107% of
prescribed dose) to these structures. Conformity index
(CI), homogeneity index (HI) together with dosimetric
parameters including the minimum, mean, maximum
and median dose, D05 (dose received by the maximal 5%
of the target), D01 (dose received by the maximal 1% of
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optic chiasm and lacrimal glands were recorded. CI,
originally proposed by ICRU 62 and later modified by
Paddick, represents the ratio to evaluate the tightness
of fit of the Planning Target Volume (PTV) to the pre-
scription isodose volume in treatment plans [15,16].
We applied the formula CI = VPTV × VTV/TV
2
PV
(VPTV: the volume of PTV; VTV: the treatment volume
encompassed by the prescribed isodose lines; TVPV: the
volume of the PTV within the prescribed isodose lines)
and HI = D5%/D95% (D5% and D95%: the dose received
by the maximal 5% and 95% of the PTV respectively)
[17,18]. Unity is considered the most ideal for both CI
and HI. The study was carried out in strict compliance
with the Helsinki Declaration. Prior approval from
local institutional review board was obtained before
the study was conducted. Written informed consent
was obtained from all patients for publication of this
report and any accompanying images.
Statistical analysis
CI, HI and other dosimetric parameters generated by
IMRT as mentioned above were compared with the
other two techniques by Mann–Whitney U tests. A
two-tailed p-value less than 0.05 was considered sta-
tistically significant. All statistical analyses were per-
formed by Statistical Packages for Social Sciences
(SPSS) version 19.
Results
The details of all 10 patients were shown in Table 1.
They all completed IMRT for their Graves’ ophthalmo-
pathy without interruption or any acute adverse events.
Mean GTV of all patients was 40.92cm3 (range: 28.52-
50.01cm3) while mean PTV was 74.29cm3 (range: 54.45-
109.22cm3).Table 1 Patient characteristics
Patient Age Sex Date of
diagnosis
of Graves’
disease
Date of
diagnosis
of Graves’
ophthalmopathy
Prior use of
systemic
steroid
Pri
corre
ey
oper
1 24 F 07/2007 10/2008 Y N
2 54 F 09/2001 11/2008 Y N
3 36 F 03/2010 08/2010 Y N
4 43 M 01/1995 01/1995 Y N
5 31 M 06/2009 06/2009 Y N
6 46 M 07/2009 07/2009 Y Y
7 72 M 07/2008 07/2008 Y N
8 47 F 01/1996 03/1996 Y Y
9 39 M 05/2009 05/2009 Y N
10 46 F 01/2003 07/2009 Y N
CMZ – carbimazole, PTU- propylthiouracil.CI and HI
Mean CI generated by IMRT was 1.24 (range: 1.15-1.30)
while those for 3DCRT and LOF were 1.74 (range: 1.42-
1.90) and 3.11 (range: 2.42-4.27) respectively. When
IMRT was compared with 3DCRT, a superior CI was
observed in IMRT (p=0.005). Likewise when IMRT was
compared with LOF, IMRT definitely resulted in a better
CI (p=0.005). Mean HI generated by IMRT, 3DCRT and
LOF were 1.05 (1.03-1.08), 1.08 (1.05-1.14), 1.60 (1.06-
4.60) respectively, with significant statistical difference in
favor of IMRT when compared with 3DCRT (p=0.007)
and LOF (p=0.005).
Comparison of dosimetric parameters of targets (Table 2)
GTV
IMRT versus 3DCRT When GTV of left and right eye
were considered individually, both the left and right eyes
received a significantly higher minimum (p=0.005 for
both left and right eyes) with IMRT. When they were
combined together to form a single GTV, again IMRT
offered less cold spots than 3DCRT as reflected by a
higher minimum dose received by the GTV (p=0.005)
(Table 2).
IMRT versus LOF The GTV of both eyes, when consid-
ered individually, received a higher minimum (left:
p=0.005; right p=0.005) and a mean dose (left: p=0.008;
right: p=0.005) with IMRT. When added together to
form single GTV of both eyes, IMRT was able to give a
higher minimum and mean dose (p=0.005 for both
respectively).
PTV
IMRT versus 3DCRT When dividing PTV according to
individual eye, both the left and right eyes had a higher
minimum (p=0.005 for both eyes) and mean dose (left:or
ctive
e
ation
Prior radio-
iodine
therapy
Time between
diagnosis to
radiotherapy
(months)
Use of systemic
steroid during
radiotherapy
Use of
anti-thyroid
drugs during
radiotherapy
N 14 Y CMZ
Twice 8 Y N
N 3 N N
N 180 Y N
N 8 Y N
N 12 Y N
N 10 Y PTU
N 156 Y N
N 8 Y N
N 4 N PTU
Table 2 Dosimetric parameters of GTV and PTV planned by three different treatment techniques
Parameters (mean[range], Gy) LOF 3DCRT IMRT
GTV
Minimum 5.03 [0.46-9.28] 7.30 [5.43-9.54] 9.85 [9.56-9.98]**,##
Maximum 10.66 [10.58-10.86] 10.61 [10.55-10.68] 10.72 [10.52-11.03]
Mean 10.09 [9.49-10.27] 10.30 [10.27-10.34] 10.32 [10.27-10.44]##
Median 10.27 [10.11-10.36] 10.34 [10.30-10.37] 10.31 [10.27-10.44]
D05 10.50 [10.37-10.59] 10.50 [10.46-10.54] 10.49 [10.41-10.69]
D01 10.57 [10.47-10.73] 10.54 [10.50-10.60] 10.56 [10.45-10.80]
PTV
Minimum 3.77 [0.35-7.95] 5.72 [3.98-8.53] 8.61 [6.85-9.53]**,##
Maximum 10.67 [10.59-10.87] 10.61 [10.56-10.69] 10.76 [10.52-11.03]*
Mean 9.86 [8.85-10.21] 10.19 [10.10-10.24] 10.26 [10.20-10.35]**,##
Median 10.23 [10.07-10.58] 10.28 [10.20-10.32] 10.28 [10.23-10.39]
D05 10.49 [10.39-10.59] 10.49 [10.45-10.53] 10.47 [10.40-10.67]
D01 10.57 [10.49-10.72] 10.54 [10.50-10.61] 10.55 [10.44-10.78]
* p<0.05, ** p<0.01 compared with 3DCRT.
# p<0.05, ## p<0.01 compared with LOF.
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combined together to be a single PTV, a higher mini-
mum (p<0.001), maximum (p=0.022) and mean dose
(p=0.007) could be achieved by IMRT.
IMRT versus LOF When PTV was considered individu-
ally, both the left and right eyes received a higher mini-
mum (p=0.005 for both eyes) and mean dose (left:
p=0.007; right: p=0.005) with IMRT. Apart from that,
the right eyes also received a higher median dose
(p=0.005). When they were combined together to be-
come a single PTV, a higher minimum and mean dose
(p=0.005 for both) could be observed when planned with
IMRT.
Comparison of dosimetric parameters of OARs (Table 3)
Globes
IMRT vs 3DCRT IMRT provided a better sparing to the
globes compared with 3DCRT. The left globes received a
reduced mean (p=0.007), median (p=0.008) and D05
(p=0.041) with IMRT. Similarly, the right globes were also
better spared with unnecessary irradiation with IMRT, with
a reduced minimum (p=0.009), mean (p=0.009), median
(p=0.012) and D05 (p=0.028) (Table 3).
IMRT vs LOF There was no statistical difference in all
dosimetric parameters for both globes when comparing
IMRT versus LOF. It was originally thought that LOF, as
compared with IMRT, would contribute less radiation to
the globes as their anterior portions were not within the
radiation portals of LOF, it was not demonstrated in our
study however. The reason was that the anterior thirds
of the globes still received some dose owing to radiationfalloff and scattered radiation in LOF. This gave rise to
the result that, despite lower value of parameters gener-
ated by LOF, they were not statistically different from
those generated by IMRT.
Lenses
IMRT versus 3DCRT Similar to the globes, IMRT def-
initely produced better sparing to the both lenses com-
pared with 3DCRT, with a reduced minimum (p=0.005
both lenses), maximum (left: p=0.009; right: p=0.013),
mean (left: p=0.005; right: p=0.007), median (left:
p=0.005; right: p=0.007), D05 (p=0.013 for both lenses)
and D01 (left: p=0.009; right: p=0.017).
IMRT versus LOF There was no difference in all dosi-
metric parameters for both lenses between IMRT and
LOF. Similar to the globes, though the lenses were not
included in the radiation portals of LOF, they still
received certain radiation due to falloff and scattered ra-
diation. This resulted in numerically lower values of the
parameters achieved by LOF, but statistical differences
were not found when compared with IMRT.
Optic nerves
IMRT versus 3DCRT IMRT produced some dose spar-
ing to both the left and right optic nerves. The median
dose (p=0.028) and D05 (p=0.038) of left optic nerve
was slightly reduced and the mean (p=0.037) and me-
dian dose (p=0.021) of the right optic nerve was also
slightly improved when planned by IMRT.
IMRT versus LOF IMRT produced a slightly higher mini-
mum dose to the optic nerves (left: p=0.022; right: p=0.110)
Table 3 Dosimetric parameters of OARs planned by three radiation treatment techniques
Parameters
(mean[range], Gy)
LOF 3DCRT IMRT
Left globe
Minimum 1.16 [0–6.64] 2.88 [0.59-4.35] 3.17 [1.23-9.98]
Maximum 10.56 [10.47-10.74] 10.57 [10.48-10.69] 10.57 [10.34-11.03]
Mean 7.53 [5.60-10.10] 9.08 [8.26-9.53] 8.55 [7.54-10.32]**
Median 8.33 [5.80-10.23] 9.96 [9.19-10.64] 9.26 [8.15-10.30]**
D05 10.39 [10.15-10.53] 10.47 [10.29-10.61] 10.34 [10.20-10.53]*
D01 9.48 [0.44-10.66] 10.00 [5.30-10.65] 10.44 [10.27-10.73]
Right globe
Minimum 1.48 [0.21-7.31] 3.35 [1.95-4.57] 2.27 [0.55-3.93]**
Maximum 10.55 [10.45-10.74] 10.55[10.46-10.64] 10.51 [10.37-10.89]
Mean 7.66 [5.98-10.06] 9.09 [8.41-9.74] 8.37 [7.27-9.09]**
Median 8.51 [6.35-10.16] 9.86 [9.29-10.29] 9.23 [7.84-9.93]*
D05 10.37 [10.19-10.51] 10.44 [10.27-10.55] 10.31 [10.22-10.55]*
D01 10.47 [10.31-10.65] 10.50 [10.37-10.59] 10.40 [10.27-10.71]
Left lens
Minimum 1.91 [0.43-8.23] 4.51 [3.82-4.88] 3.06 [1.86-4.39]**
Maximum 4.93 [1.92-10.04] 7.47 [7.13-8.20] 5.67 [3.82-7.64]**
Mean 3.12 [0.88-9.65] 5.71 [5.33-6.25] 4.14 [2.62-5.60]**
Median 3.05 [0.85-9.84] 5.69 [5.18-6.20] 4.09 [2.46-5.55]**
D05 4.26 [1.47-10.03] 6.87 [6.58-7.33] 5.15 [3.53-7.15]*
D01 4.59 [1.91-10.04] 7.20 [6.89-7.77] 5.43 [3.64-7.44]**
Right lens
Minimum 2.01 [0.39-8.22] 4.52 [3.70-5.14] 3.05 [1.86-4.32]**
Maximum 4.94 [2.18-9.91] 7.41 [6.68-7.93] 5.59 [3.79-7.78]*
Mean 3.24 [1.05-9.49] 5.77 [5.20-6.42] 4.12 [2.57-5.46]**
Median 3.13 [0.91-9.49] 5.74 [5.15-6.45] 4.07 [2.48-5.45]**
D05 4.45 [2.15-9.83] 6.90 [6.26-7.38] 4.93 [3.37-7.03]*
D01 4.76 [2.17-9.89] 7.21 [6.54-7.71] 5.39 [3.57-7.53]*
Left optic nerve
Minimum 9.68 [9.24-10.24] 9.88 [9.17-10.24] 9.99 [9.76-10.16]#
Maximum 10.51 [10.41-10.59] 10.51 [10.46-10.55] 10.42 [10.22-10.57]#
Mean 10.29 [10.09-10.43] 10.33 [10.23-10.39] 10.25 [10.10-10.36]
Median 10.32 [10.11-10.43] 10.34 [10.27-10.40] 10.25 [10.11-10.38]*
D05 10.46 [10.30-10.55] 10.45 [10.38-10.51] 10.35 [10.17-10.49]*,#
D01 10.49 [10.36-10.51] 10.48 [10.41-10.52] 10.38 [10.17-10.53]#
Right optic nerve
Minimum 9.82 [9.25-10.31] 10.04 [9.83-10.28] 10.08 [9.93-10.22]
Maximum 10.51 [10.35-10.62] 10.51 [10.43-10.58] 10.49 [10.27-10.76]
Mean 10.31 [10.14-10.46] 10.35 [10.24-10.40] 10.26 [10.08-10.36]*
Median 10.34 [10.20-10.45] 10.37 [10.27-10.46] 10.26 [10.08-10.36]*,#
D05 10.46 [10.30-10.57] 10.47 [10.38-10.54] 10.39 [10.18-10.53]#
D01 10.49 [10.32-10.60] 10.49 [10.41-10.57] 10.44 [10.22-10.67]
Lee et al. Radiation Oncology 2012, 7:199 Page 5 of 9
http://www.ro-journal.com/content/7/1/199
Table 3 Dosimetric parameters of OARs planned by three radiation treatment techniques (Continued)
Optic chiasm
Minimum 0.28 [0.09-0.68] 2.30 [1.84-3.01] 3.38 [0.99-9.76]##
Maximum 6.72 [0.41-9.84] 8.30 [5.13-9.65] 8.32 [3.60-10.35]
Mean 1.57 [0.16-3.49] 3.94 [2.67-5.64] 4.84 [1.44-10.15]##
Median 1.02 [0.14-3.11] 3.46 [2.52-5.55] 4.55 [1.35-10.14]##
D05 4.71 [0.29-7.97] 6.76 [3.78-8.29] 6.95 [2.19-10.24]#
D01 6.01 [0.35-9.39] 7.72 [4.56-9.10] 7.68 [2.84-10.29]
Left lacrimal gland
Minimum 3.63 [0.79-8.98] 5.88 [3.62-7.37] 6.24 [4.18-8.39]#
Maximum 9.27 [0.86-10.56] 10.43 [9.96-10.68] 10.52 [10.20-10.84]#
Mean 8.06 [5.84-10.03] 9.11 [7.73-9.80] 9.25 [7.94-10.28]#
Median 8.32 [5.78-10.06] 9.34 [8.00-9.96] 9.46 [8.04-10.34]#
D05 9.97 [9.27-10.75] 10.23 [9.65-10.60] 10.34 [9.81-10.66]#
D01 10.13 [9.48-10.82] 10.36 [9.83-10.65] 10.44 [10.00-10.81]#
Right lacrimal gland
Minimum 3.57 [0.85-8.99] 5.36 [3.07-7.12] 5.21 [3.11-7.33]
Maximum 10.28 [9.83-10.81] 10.35 [9.77-10.61] 10.44 [10.14-10.74]
Mean 8.18 [5.67-9.92] 8.89 [7.64-9.87] 8.94 [6.87-10.17]
Median 8.54 [5.84-9.95] 9.14 [7.87-10.22] 10.26 [6.81-10.30]
D05 9.99 [9.08-10.74] 10.15 [9.41-10.52] 10.29 [9.89-10.58]#
D01 10.16 [9.50-10.78] 10.28 [9.59-10.56] 10.39 [10.09-10.63]#
* p<0.05, ** p<0.01 compared with 3DCRT.
# p<0.05, ## p<0.01 compared with LOF.
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were totally encompassed by the PTV. The improved
coverage of PTV inevitably led to an increased minimum
dose to the optic nerves. However weightings were given to
the optic nerves during IMRT optimization so that hot
spots did not fall within them. It was reflected by a lower
maximum dose (p=0.038), D05 (p=0.011) and D01
(p=0.028) to the left optic nerve and a lower median dose
(p=0.037) and D05 (p=0.047) to the right optic nerve.Optic chiasm
IMRT versus 3DCRT There were no significant statis-
tical differences in the dosimetric parameters of the
optic chiasm between IMRT and 3DCRT, though they
were all slightly higher when planned by IMRT.
IMRT versus LOF IMRT produced a higher minimum
(p=0.005), mean (p=0.007), median (p=0.007), D05
(p=0.022) to the optic chiasm as compared with LOF.
This was because the IMRT beams directed from poster-
ior to anterior contributed to the increased dose to the
optic chiasm in contrast to the steep drop of radiation
dose in that region delivered by LOF.Lacrimal glands
IMRT versus 3DCRT There were no significant statis-
tical differences in the dosimetric parameters of the both
lacrimal glands between IMRT and 3DCRT, though
again they were all slightly higher when planned by
IMRT.
IMRT versus LOF IMRT produced a higher minimum
(p=0.017), maximum (p=0.013), mean (p=0.022) and me-
dian dose (p=0.047) as well as D05 (p=0.047) and D01
(p=0.047) to the left lacrimal glands. Similarly, D05
(p=0.047) and D01 (p=0.041) of the right lacrimal glands
were also higher with IMRT. The lacrimal glands, as
situated anteriorly in the globe at the upper outer quad-
rants of the conjunctiva, were not within the radiation
portals when planned by LOF. As the most anterior por-
tions of the globes were blocked from radiation in LOF,
the lacrimal glands, as a result, were also blocked from
radiation as well. The dose to the lacrimal glands was
thus lower with LOF.
Planning time, treatment time and monitor units
The average planning time for an IMRT plan by our
experienced physicists and dosimetrists was around 2
Figure 2 Dose distribution and target coverage by IMRT
(uppermost), LOF (middle) and 3DCRT (lowermost).
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3DCRT and LOF plan respectively. Similarly treatment
time of each fraction for IMRT was also longer (26 min-
utes) than that delivered for a 3DCRT (16 minutes) and
LOF (10 minutes). Average monitor units (MU) con-
sumed was greater for IMRT (773 MU), in contrast to
that for 3DCRT (252 MU) and LOF (197 MU).
Radiation-induced cataract based on NTCP model
The lenses are the only potential critical organs which
might suffer from radiotherapy-induced complications
like cataract, since we only delivered a low dose of radi-
ation to the orbits. We calculated their normal tissue
complication probability (NTCP) after treatment with
each radiation technique, based on the equivalent uni-
form dose (EUD) and the following formula: NTCP ¼
1
1þ TD50EUDð Þ4γ50
, where TD50 is the tolerance dose for a 50%
complication rate at a specific time interval when the
whole organ of interest is homogeneously irradiated and
γ50 is a model parameter that is specific to the normal
tissue and describes the slope of the dose response curve
[19-21]. Ranges of values NTCP of the left lens contrib-
uted by LOF, 3DCRT and IMRT were 0.003-3.194,
0.213-0.429 and 0.010-0.280 respectively. Similarly
NTCP for the right lens contributed by LOF, 3DCRT
and IMRT were 0.001-2.942, 0.188-0.480 and 0.009-
0.236 respectively. Statistical comparison demonstrated
that NTCP contributed by IMRT was higher than that
contributed 3DCRT (left: p=0.001; right: p=0.013) but
not higher than that by LOF (left: p=0.096; right:
p=0.257), revealing the risk of radiation-induced cataract
might be higher for IMRT as compared 3DCRT but not
with LOF.
Discussion
Graves’ ophthalmopathy is the commonest extrathryoi-
dal manifestation of Graves’ disease [1,2,22]. Clinical
presentations include proptosis, eyelid swelling and re-
traction, chemosis, compressive optic neuropathy and
papilloedema. The underlying pathogenesis is believed
to be autoimmune-related leading to excessive infiltra-
tion of lymphocytes and excessive production of hydro-
philic glycosaminoglycans and subsequently expansion
of retro-orbital tissues and enlargement of extraocular
muscles. Treatment options include steroid therapy, cor-
rective/decompressive surgery, radiation therapy or
combination of these approaches [3-5,23]. Orbital irradi-
ation has been practiced for more than 60 years. It is
usually reserved for cases with moderate and severe de-
gree of exophthalmos or compressive optic neuropathy
when decompressive surgery is not immediately available
or if patients are medically contraindicated for surgery.
Though producing conflicting and controversial resultsas demonstrated in several double-blind randomized-
controlled trials and numerous non-randomized trials
with a small potential risk of long-term adverse events,
orbital irradiation is still an acceptable treatment option
for such disease [24-29]. There are also disputes on the
optimal dose of orbital irradiation [30,31]. For studies in
favor of orbital irradiation, they used delivered 20Gy in
10 fractions over 2 weeks as the standard dose while
more recent studies demonstrated that a lower dose was
also equally effective. A randomized study revealed treat-
ment with 20Gy of 1Gy-fraction weekly over 20 weeks
was more effective and better tolerated than treatment
with 20Gy of 2Gy-fraction over 2 weeks and 10Gy of
1Gy-fraction over 2 weeks [30]. The dose prescription in
our study was based on this study after taking the bal-
ance between the total dose and the total treatment dur-
ation into consideration. LOF technique has been
employed by radiation oncologists for many decades in
virtue of its simple and swift set-up procedures.
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sufficient dose to the insertions of the extraocular mus-
cles and the most anterior portion of the retro-orbital
fat which are commonly involved in Graves’ ophthalmo-
pathy, as well as inhomogeneous dose distribution
within the target, since the anterior portion of the globes
are usually blocked from the radiation portals of LOF in
order to reduce the dose to the lenses. 3DCRT and
IMRT, widely adopted for more than 10 years, were
regarded as the current standard radiation treatment
technique for head and neck and orbital tumors [6-10].
However there has been so far no study regarding the
use of IMRT as the treatment technique for Graves’
ophthalmopathy and only a few studies of using IMRT
for other orbital diseases [6,11,12].
In our dosimetric study, we were able to demonstrate
that IMRT offered a superior and more conformal
coverage of the GTV and PTV compared with 3DCRT
and LOF resulting in a better CI (Figure 2). Part of the
PTV of our patients was just covered by 70% isodose
curves in the plans generated by 3DCRT and LOF while
almost 100% of GTV and most of PTV were adequately
covered by 95% of prescribed dose in the plans gener-
ated by IMRT except at areas close to the ethmoid
sinuses where attenuation in the air is low. The superior-
ity of PTV coverage by IMRT could also be reflected by
a more favorable dose volume histogram (DVH) in con-
trast to 3DCRT and LOF (Figure 3). On top of that,
more effective elimination of hot and cold spots
achieved by IMRT resulted in a more favorable HI.
When compared with 3DCRT, IMRT could also better
preserve adjacent normal structures including the
globes, lenses and the optic nerves in virtue of its betterFigure 3 Dose volume histogram of PTV generated by IMRT (blue), 3Ddose fall off and steeper gradient. When comparing
IMRT against LOF, IMRT inevitably resulted in a higher
dose to the optic nerves and optic chiasm. The resultant
increased dose to these structures was due to the extra
dose contributed by the posteriorly-oriented beams in
IMRT. LOF though could achieve dose sparing to the
lacrimal glands as well as to a lesser extent and non-
significant sparing to the lenses in our study since they
were blocked from its radiation portals, it also compro-
mised the PTV coverage of the insertions of the extrao-
cular muscles and anterior part of the retro-orbital fat.
Another drawback of IMRT was the increased risk of
radiation-induced complication like cataract as demon-
strated in our NTCP model, but the risk was very small
and clinically negligible. Having all these considered to-
gether, the dosimetric advantages achieved by IMRT still
made it an acceptable and encouraging radiation tech-
nique despite the longer treatment planning and delivery
time, extra monitor units consumed as well as the
slightly increased but clinically negligible dose to some
nearby normal structures. The clinical outcomes of
patients with Graves’ ophthalmopathy may improve after
treatment with IMRT owing to its better target coverage
especially over the insertions of extraocular muscles and
the anterior part of the retro-orbital fat. A long follow
up is definitely warranted to observe the clinical out-
comes and complications after IMRT.
Conclusion
IMRT is an acceptable radiation treatment technique for
Graves’ ophthalmopathy in virtue of its superior target
coverage, better CI and HI, despite an increase inCRT (yellow) and LOF (red) in a patient.
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http://www.ro-journal.com/content/7/1/199treatment planning and delivery time, consumption of
monitor units and a slightly increased but clinically neg-
ligible dose to some surrounding structures. It might
supersede the other two older radiation techniques when
orbital irradiation is contemplated.
Competing interests
The authors declare that actual or potential conflicts of interest do not exist.
Authors’ contribution
VHFL, SCYN, CWC, MYL, TWL, GKHA, and DLWK participated in the study
design and coordination, performed acquisition of data, and drafted the
manuscript. VHFL and CWC participated in the statistical data analysis. All
authors reviewed and approved the final manuscript.
Author details
1Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The
University of Hong Kong, 1/F, Professorial Block, Queen Mary Hospital, 102
Pokfulam Road, Pokfulam, Hong Kong. 2Department of Community
Medicine, School of Public Health, Li Ka Shing Faculty of Medicine, The
University of Hong Kong, 7 Sassoon Road, Hong Kong, Hong Kong.
Received: 22 April 2012 Accepted: 10 November 2012
Published: 26 November 2012
References
1. Burch HB, Wartofsky L: Graves’ ophthalmopathy: current concepts
regarding pathogenesis and management. Endocr Rev 1993, 14:747–793.
2. Bahn RS, Heufelder AE: Pathogenesis of graves’ ophathlmopathy. N Eng J
Med 1993, 329:1468–1474.
3. Prummel MF, Mourits MP, Blank L, et al: Randomized double-blind trial of
prednisone versus radiotherapy in graves’ ophthalmopathy. Lancet 1993,
342:949–954.
4. Trokel S, Kazin M, Moore S: Orbital fat removal. Decompression for graves’
orbitopathy. Ophthalmol 1993, 100:674–682.
5. Hallin ES, Feldon SE, Lutrell J: Graves’ ophthalmopathy: effect of
transantral orbital decompression on optic neuropathy. J Ophthalmol
1988, 72:683–687.
6. Goyal S, Cohler A, Camporeale J, et al: Intensity-modulated radiation
therapy for orbital lymphoma. Radiat Med 2008, 26(10):573–581.
7. Chao KS, Deasy JO, Markman J, et al: A prospective study of salivary
function sparing in patients with head-and-neck cancers receiving
intensity-modulated or three-dimensional radiation therapy: initial
results. Int J Radiat Oncol Biol Phys 2001, 49:907–916.
8. Eisbruch A, Ship JA, Dawson LA, et al: Salivary gland sparing and
improved target irradiation by conformal and intensity modulated
irradiation of head-and-neck cancer. World J Surg 2003, 27:832–837.
9. Nutting CM, Morden JP, Harrington KJ, et al: Parotid- sparing intensity
modulated versus conventional radiotherapy in head-and-neck cancer
(PARSPORT): a phase 3 multicentre randomized controlled trial. Lancet
Oncol 2011, 12:127–136.
10. Eisbruch A, Schwartz M, Rasch C, et al: Dysphagia and aspiration after
chemoradiotherapy for head-and-neck cancer: which anatomic
structures are affected and can they be spared by IMRT? Int J Radiat
Oncol Biol Phys 2004, 60:1425–1439.
11. Al-Wassia R, Dal Pra A, Shun K, et al: Stereotactic fractionated radiotherapy
in the treatment of juxtapapillary choroidal melanoma: the McGill
university experience. Int J Radiat Oncol Biol Phys 2011, 81(4):e455–e462.
12. Hirschbein MJ, Collins S, Jean WC, et al: Treatment of intra-orbital lesions
using the accuray CyberKnife system. Orbit 2008, 27(2):97–105.
13. Ulmer W, Pyyry J, Kaissl W: A 3D photon superposition/convolution
algorithm and its foundation on results of Monte Carlo calculations.
Phys Med Biol 2005, 50:1767–1790.
14. Bragg CM, Wingate K, Conway J: Clinical implications of the anisotropic
analytical algorithm for IMRT treatment planning and verification.
Radiother Oncol 2008, 86(2):276–284.
15. ICRU: Prescribing, recording and reporting photon beam therapy (supplement
to ICRU report 50). Bethesda, MD: International Commission of Radiation
Units and Measurements: ICRU 62; 1999.16. Paddick I: A simple scoring ratio to index the conformity of plans.
J Neurosurg 2000, 93(Suppl. 3):219–222.
17. Sheng K, Molloy JA, Larner JM, Read PW: A dosimetric comparison of
non-coplanar IMRT versus Helical Tomotherapy for nasal cavity and
paranasal sinus cancer. Radiother Oncol 2007, 82:174–178.
18. Wang X, Zhang X, Dong L, et al: Effectiveness of noncoplanar IMRT
planning using a parallelized multiresolution beam angle optimization
method for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2005,
63:594–601.
19. Niemierko A: Radiobiological models of tissue response to radiation in
treatment planning systems. Tumori 1998, 84(2):140–143.
20. Niemierko A: Reporting and analyzing dose distributions: a concept of
equivalent uniform dose. Med Phys 1997, 24(1):103–110.
21. Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to
therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109–122.
22. Bartalena L, Marcocci C, Tanda ML, et al: Cigarette smoking and
treatment outcomes in graves ophthalmopathy. Ann Intern Med 1998,
129(8):632–635.
23. Ohtsuka K, Sato A, Kawaguchi S, et al: Effect of pulse steroid therapy with
and without orbital radiotherapy on graves’ ophthalmopathy. Am J
Ophthalmol 2003, 135(3):285–290.
24. Gorman CA, Garrity JA, Fatourechi V, et al: The aftermath of orbital
radiotherapy for graves’ ophthalmopathy. Ophthalmology 2002,
109(11):2100–2107.
25. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al: Radiotherapy for
graves’ orbitopathy: randomized placebo-controlled study. Lancet 2000,
355(9214):1505–1509.
26. Marquez SD, Lum BL, McDougall IR, et al: Long-term results of irradiation
for patients with progressive graves’ ophthalmopathy. Int J Radiat Oncol
Biol Phys 2001, 51(3):766–774.
27. Prummel MF, Terwee CB, Gerding MN, et al: A randomized controlled trial
of orbital radiotherapy versus sham irradiation in patients with mild
graves’ ophthalmopathy. J Clin Endocrinol Metab 2004, 89(1):15–20.
28. Wakelkamp IM, Tan H, Saeed P, et al: Orbital irradiation for graves’
disease. Is it safe? a long-term follow-up study. Ophthalmology 2004,
111(8):1557–1562.
29. Akmansu M, Dirican B, Bora H, et al: The risk of radiation-induced
carcinogenesis after external beam radiotherapy of graves’ orbitopathy.
Ophthalmic Res 2003, 35:150–153.
30. Kahaly GJ, Rosler H, Pitz S, et al: Low- versus high-dose radiotherapy for
graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol
Metab 2000, 85(1):102–108.
31. Gerling J, Kommerell G, Henne K, et al: Retrobular irradiation for
thyroid-associated orbitopathy-double blind comparison between 2.4
and 16Gy. Int J Radiat Oncol Biol Phys 2003, 55(1):582–589.
doi:10.1186/1748-717X-7-199
Cite this article as: Lee et al.: Comparative analysis of dosimetric
parameters of three different radiation techniques for patients with
Graves’ ophthalmopathy treated with retro-orbital irradiation. Radiation
Oncology 2012 7:199.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
